Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Therapeutic Drug Monitoring: Drug Analysis Methods

Therapeutic Drug Monitoring: Drug Analysis Methods

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...

Measurement of Bioavailability: Pharmacodynamic Methods

Measurement of Bioavailability: Pharmacodynamic Methods

Pharmacodynamic methods provide insights into a drug's effects on physiological processes over time and play a crucial role in understanding bioavailability and therapeutic efficacy. These methods can be broadly classified into acute pharmacological and therapeutic response approaches, each with distinct mechanisms and applications.The acute pharmacological response method directly correlates a drug's physiological effects, such as ECG or pupil diameter changes, to its time course in the body.

Drug Dosing: Geriatric Patients

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Stage-by-stage formation of superficial nanostructures in ITO films reduced by H<sub>2</sub>-GD at low temperature (100 °C) for applications on plastic substrates.

Nanotechnology·2020

Same author

Pharmacological Approaches to the Management of Secondary Progressive Multiple Sclerosis.

Drugs·2017

Same author

Anti-JC virus antibody titres increase over time with natalizumab treatment.

Multiple sclerosis (Houndmills, Basingstoke, England)·2015

Same author

Technical assessment of whole body angiography and cardiac function within a single MRI examination.

Clinical radiology·2015

Same author

Age independently affects myelin integrity as detected by magnetization transfer magnetic resonance imaging in multiple sclerosis.

NeuroImage. Clinical·2014

Same author

Curable focal epilepsy.

QJM : monthly journal of the Association of Physicians·2012

Search research articles

Related Experiment Video

Updated: May 10, 2026

A Randomized, Sham-Controlled Trial of Cranial Electrical Stimulation for Fibromyalgia Pain and Physical Function, Using Brain Imaging Biomarkers

A Randomized, Sham-Controlled Trial of Cranial Electrical Stimulation for Fibromyalgia Pain and Physical Function, Using Brain Imaging Biomarkers

Published on: January 5, 2024

Assessing dalfampridine efficacy in the physician's office.

J B Raffel¹, O Malik, R S Nicholas

¹Department of Neurology, Imperial College Healthcare NHS Trust, London, UK.

Multiple Sclerosis (Houndmills, Basingstoke, England)

|June 4, 2013

Summary

Dalfampridine improves walking speed in some multiple sclerosis patients. Identifying which patients benefit most from this treatment remains a critical clinical challenge not yet fully addressed in research.

Keywords:

4-Aminopyridine cost benefit analysis multiple sclerosis treatment outcome walking speed

More Related Videos

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

Related Experiment Videos

Last Updated: May 10, 2026

A Randomized, Sham-Controlled Trial of Cranial Electrical Stimulation for Fibromyalgia Pain and Physical Function, Using Brain Imaging Biomarkers

A Randomized, Sham-Controlled Trial of Cranial Electrical Stimulation for Fibromyalgia Pain and Physical Function, Using Brain Imaging Biomarkers

Published on: January 5, 2024

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

Area of Science:

Neurology
Clinical Pharmacology

Background:

Dalfampridine (extended release 4-aminopyridine) has demonstrated efficacy in improving walking speed in multiple sclerosis (MS).
Evidence from randomized controlled trials indicates that only a subset of MS patients experience significant benefits from dalfampridine treatment.

Purpose of the Study:

To address the clinical challenge of identifying MS patients who are likely to achieve meaningful therapeutic benefits from dalfampridine.
To bridge the gap between trial findings and practical clinical decision-making for neurologists regarding dalfampridine prescription.

Main Methods:

Review of recent randomized controlled trials on dalfampridine in multiple sclerosis.
Analysis of existing literature to identify patterns or predictors of treatment response.
Synthesis of clinical trial data to inform patient selection strategies.

Main Results:

Dalfampridine's effectiveness in improving walking speed is confirmed but patient response is variable.
The literature currently lacks clear guidelines or validated methods for predicting individual patient response to dalfampridine.
A significant unmet need exists for tools to differentiate responders from non-responders in clinical practice.

Conclusions:

While dalfampridine offers a potential benefit for walking in MS, patient selection is crucial.
Further research is needed to develop predictive markers or clinical tools for dalfampridine therapy.
Clinicians require better evidence to guide the use of dalfampridine in individual multiple sclerosis patients.